Print Page      Close Window     

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 11, 2018
CORRECTION: Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
BUFFALO, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by Athenex, Inc., please note that the dosing regimen should be “mg/m2,” rather than “mg/kg,” as was stated in the earlier release. The corrected press release follows: Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that its global Phase 1b clinical trial... 
Printer Friendly Version 
December 11, 2018
Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
BUFFALO, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that its global Phase 1b clinical trial of Oraxol (oral paclitaxel plus HM30181A) plus ramucirumab (monoclonal antibody to VEGF-R2) in gastric cancer patients who failed previous chemotherapies has completed the study of the second cohort of patients. The results indicated... 
Printer Friendly Version 
December 06, 2018
Athenex to Host an R&D Day on December 17 in New York
BUFFALO, N.Y., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will host an R&D Day on Monday, December 17, 2018, from 12 noon to 3:00 pm Eastern Time, in New York City. The Company will provide an overview of the R&D pipeline and updates on key clinical programs. Discu... 
Printer Friendly Version 
November 29, 2018
Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories
BUFFALO, N.Y., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into an agreement with PharmaEssentia Corporation (Taipei Exchange:6446) to license the rights to develop and commercialize Athenex’s Oradoxel in Taiwan, Singapore and Vietnam. The existing licensing agreement for O... 
Printer Friendly Version 
November 26, 2018
Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has initiated a Phase I/II clinical study to assess the safety, tolerability and activity of Oraxol in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced solid malignancies, in collaboration with May... 
Printer Friendly Version 
November 14, 2018
Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Third quarter revenue increased to $18.4 million compared to $14.0 million in 3Q 2017 Positive recommendation by DSMB upon second interim analysis for Oraxol Phase III program KX2-391 Phase III pivotal studies achieved primary endpoints Oratecan and Oradoxel are ready to advance to Phase II Conference call and live audio webcast at 8:00 a.m. Eastern Time today BUFFALO, N.Y., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to th... 
Printer Friendly Version 
November 01, 2018
Athenex, Inc. to Report Third Quarter Earnings Results on November 14, 2018
BUFFALO, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter 2018 and nine months ended September 30, 2018 earnings results on November 14, 2018 before the market opens. The Company will host a conference call and live audio webcast on Wednesday, November 14, 2... 
Printer Friendly Version 
October 29, 2018
Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials
BUFFALO, N.Y., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the FDA has allowed the Investigational New Drug (IND) application for Athenex's oral version of Eribulin currently named Eribulin ORA. This FDA action allows Athenex to commence its clinical trial program, currently planned fo... 
Printer Friendly Version 
October 22, 2018
ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer
BUFFALO, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the presentation of encouraging efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients who failed previous chemotherapies in a pharmacokinetics (PK) and phase II clinical trial conducted in Taiwan.... 
Printer Friendly Version 
October 16, 2018
Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress
BUFFALO, N.Y., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that results of the Oraxol (oral paclitaxel and HM30181A) pharmacokinetics and phase II clinical trial in the treatment of breast cancer patients who failed previous chemotherapies will be presented on October 21, 2018 at a Poster Disc... 
Printer Friendly Version 
October 15, 2018
Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
BUFFALO, N.Y., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy (“TAEST”) showed encouraging positive clinical signals in terms of efficacy and safety.  The pil... 
Printer Friendly Version 
September 12, 2018
Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, and its business partner, Hanmi Pharmaceutical, today announced a strategic realignment of their joint projects to further explore and develop those projects worldwide.  Under the realignment, Athenex and Hanmi Pharmaceutical agree to new arrangeme... 
Printer Friendly Version 
September 05, 2018
Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program
BUFFALO, N.Y., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the planned second interim analysis of the Oraxol 001 Phase III Clinical Trial in metastatic breast cancer has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB). The DSMB congratulated Athenex on th... 
Printer Friendly Version 
August 20, 2018
Athenex Appoints Randoll Sze as Chief Financial Officer
BUFFALO, N.Y., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Randoll Sze as Chief Financial Officer of the company. Mr. Sze will report to Athenex’s Chief Executive Officer. Since October 2017, Mr. Sze has served as Director of Corporate Development and Investor Relations, ... 
Printer Friendly Version 
August 14, 2018
Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update
Second quarter revenue increased to $11.6 million compared to $4.6 million in the same period last year. Received a strategic investment of $100 million from Perceptive Advisors Primary endpoints achieved in two Phase 3 trials of KX2-391 in Actinic Keratosis In-licensed an immunotherapy platform based on T-cell receptor-engineered T cells (TCR-T), and a metabolic based oncology candidate BUFFALO, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutica... 
Printer Friendly Version 
August 13, 2018
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of compounded Vasopressin Injection in ready-to-use premix IV bags through its subsidiary Athenex Pharma Solutions (APS).   APS is focused on applying pharmaceutical cGMP expertise to the 503(B) market to address hospital needs for high-quality... 
Printer Friendly Version 
August 09, 2018
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
BUFFALO, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the United States Food and Drug Administration (“FDA”) has granted clearance for Athenex Pharmaceutical Division (“APD”) to import Potassium Chloride Injection Concentrate (2 mEq/mL) in response to a national drug shortage of that product.  This FDA cle... 
Printer Friendly Version 
August 03, 2018
Athenex, Inc. to Report Second Quarter Earnings Results on August 14, 2018
BUFFALO, N.Y., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release second quarter 2018 and six months ended June 30, 2018 earnings results on August 14, 2018 before the market opens. The Company will host a conference call and live audio webcast on Tuesday, August 14, 2018 at 9:00... 
Printer Friendly Version 
July 26, 2018
Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
BUFFALO, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that both Phase 3 studies, KX-AK-003 and KX-AK-004, had achieved their primary endpoint of 100% clearance of actinic keratosis (AK) lesions at Day 57 within the face or scalp treatment areas, with each study achieving statistical signif... 
Printer Friendly Version 
July 18, 2018
Athenex Announces Axis Therapeutics Has Entered into a MOU with the Hong Kong Polytechnic University to Set Up a Joint Research Center on Cancer Immunotherapy
BUFFALO, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Axis Therapeutics Limited has entered into a Memorandum of Understanding (MOU) with the Hong Kong Polytechnic University to explore the establishment of a joint research center to advance the application of immunotherapy in Hong Ko... 
Printer Friendly Version 
July 09, 2018
Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology
Mr. Cook was Previously VP and Chief Operating Officer of Oncology at Lilly BUFFALO, N.Y., July 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Timothy Cook as Senior Vice President of Global Commercial Oncology.  Mr. Cook joins Athenex to lead the commercialization efforts of th... 
Printer Friendly Version 
July 02, 2018
Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors
Collaboration with Xiangxue Pharmaceutical Expands Portfolio in to TCR-T Immunotherapy In-Licensing of a Biologic Product from Avalon BioMedical Management BUFFALO, N.Y., July 02, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into the following agreements: Establishment of... 
Printer Friendly Version 
June 15, 2018
Athenex Announces Appointment to Board of Directors
BUFFALO, N.Y., June 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Benson Tsang to the Board of Directors, effective July 1, 2018. Mr. Tsang will serve as the Chairman of the Audit and Risk Management Committee as well as a member of the Nominating and Corporate Governance Committee.... 
Printer Friendly Version 
June 04, 2018
Athenex Names Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific
BUFFALO, N.Y., June 04, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific.  Since 2016, Ms. Wang has served as a consultant for Athenex, engaged to advise on the company’s operations in Asia P... 
Printer Friendly Version 
June 04, 2018
Athenex Announces Poster Presentations at ASCO Annual Meeting
BUFFALO, N.Y., June 04, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that two posters on Oraxol will be presented at the American Society of Clinical Oncology (ASCO) Meeting, taking place June 1-5, 2018 in Chicago, IL. Abstract Title: A phase I study to evaluate safety, tolerability, pharmacokinetics ... 
Printer Friendly Version 
May 21, 2018
Athenex to Present at UBS Global Healthcare Conference
BUFFALO, N.Y., May 21, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the UBS Global Healthcare Conference in New York, NY, on Monday, May 21st, at 3:00 pm EST. The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s webs... 
Printer Friendly Version 
May 14, 2018
Athenex, Inc. Announces First Quarter 2018 Results
Significant Clinical Milestones and Record Revenue Mark Strong Start to Fiscal 2018 First Quarter 2018 and Recent Business Highlights: Received Orphan Drug Designation from the FDA for Oraxol for the treatment of angiosarcoma Generated revenue of $37.8 million for the first quarter, up from $4.6 million year-over-year, inclusive of $25.0 million licensing fee from Almirall with additional $5 million received and recorded as deferred revenue Met and exceeded patient enrollment target... 
Printer Friendly Version 
May 08, 2018
Athenex to Present at Deutsche Bank’s 43rd Annual Health Care Conference
BUFFALO, N.Y., May 08, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8th, at 2:10 pm EDT. The presentation will be webcasted, and can be accessed at the Investor Relations section of th... 
Printer Friendly Version 
May 03, 2018
Athenex, Inc. to Report First Quarter Earnings Results on May 14, 2018
BUFFALO, N.Y., May 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release first quarter 2018 earnings results on May 14, 2018. The Company will host a conference call and audio webcast on Monday, May 14, 2018 at 9:00 a.m. Eastern Time. To participate in the call, dial (855) 227-0567 (domestic) or (612) 979-991... 
Printer Friendly Version 
April 30, 2018
Athenex, Inc. Announces Transition of James Zukin from Board of Directors to Advisory Role
BUFFALO, N.Y., April 30, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the transition of James Zukin from its Board of Directors to an advisory role.  Mr. Zukin’s transition from the Board will be effective July 1, 2018.  From that date for at least six months he will serve as Senior Strategy and Business... 
Printer Friendly Version 
April 19, 2018
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
BUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan Drug Designation from the U.S. FDA for Oraxol for the treatment of angiosarcoma. Oraxol, an innovative development in the treatment of cancer, is a novel oral formulation of paclitaxel, a very effective and ... 
Printer Friendly Version 
March 27, 2018
Athenex to Present at the 17th Annual Needham Healthcare Conference
BUFFALO, N.Y., March 27, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Simon Pedder, Chief Business and Strategy Officer, will present at the 17th Annual Needham Healthcare Conference in New York City on Tuesday, March 27, 2018 at 2:00 pm EDT. The presentation will be webcasted, and can be accessed... 
Printer Friendly Version 
March 26, 2018
Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results
Fourth Quarter 2017 and Recent Business Highlights: Met enrollment targets and received positive feedback from the US FDA for Oraxol Phase III Clinical Trial in metastatic breast cancer Announced strategic partnership with Almirall for KX2-391 Ointment for the treatment of actinic keratosis Received a Promising Innovative Medicine (PIM) designation for Oraxol by the UK Medicines and Healthcare Products Regulatory Agency Completed patient enrollment for both Phase III clinical stu... 
Printer Friendly Version 
February 26, 2018
Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018
BUFFALO, N.Y., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release fourth quarter and full year 2017 earnings results on March 26, 2018. The Company will host a conference call and audio webcast on Monday, March 26, 2018 at 9:00 a.m. Eastern Time. To participate in the call, dial (855) 227-0567 (domest... 
Printer Friendly Version 
February 20, 2018
Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
BUFFALO, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Phase II clinical study data for KX2-391 for the treatment of actinic keratosis was presented by Dr. Seth Forman of Forward Clinical Trials, Tampa, at the American Academy of Dermatology Annual Meeting on February 17, 2018 in San Die... 
Printer Friendly Version 
February 16, 2018
Athenex to Present at 2018 RBC Capital Markets Healthcare Conference
BUFFALO, N.Y., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Johnson Lau, Chief Executive Officer, will present at the 2018 RBC Capital Markets Healthcare Conference in New York City on Wednesday, February 21, 2017 at 11:00 am EST. The presentation will be webcasted, and can be accessed at... 
Printer Friendly Version 
February 15, 2018
Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer
Plans for Second Interim Analysis in Third Quarter of 2018 BUFFALO, N.Y., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the enrollment of patients is on target for the Company to be able to conduct a second interim analysis in the Oraxol KX-ORAX-001 Phase III clinical trial in the third quarter o... 
Printer Friendly Version 
February 14, 2018
Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
BUFFALO, N.Y., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced early completion of patient enrollment for both Phase III clinical studies of KX2-391 Ointment for actinic keratosis indications months ahead of schedule. Actinic keratosis is a common skin condition that is induced through ultra-vio... 
Printer Friendly Version 
February 13, 2018
Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units
Strong momentum from 2017 fuels strong start for Athenex in 2018 BUFFALO, N.Y., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced recent product launches from Athenex Pharmaceutical Division (“APD”). These launches highlight the continued portfolio growth with an emphasis on oncology or oncology sup... 
Printer Friendly Version 
January 25, 2018
Athenex, Inc. Announces Pricing of Offering of Common Stock
BUFFALO, N.Y., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of a public offering of 4,300,000 shares of its common stock at a public offering price of $15.25 per share, before underwriting discounts and commissions.  In addition, Athenex has granted the underwriters a 30-day option to purc... 
Printer Friendly Version 
January 22, 2018
Athenex, Inc. Announces Proposed Offering of Common Stock
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced an underwritten public offering of 4,300,000 shares of its common stock, subject to market conditions and other factors. In addition, Athenex intends to grant the underwriters a 30-day option to purchase up to an additional 645,000 shares of ... 
Printer Friendly Version 
January 22, 2018
Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced encouraging preliminary efficacy and safety data of Oraxol in the treatment of breast cancer in a pharmacokinetics (PK) and Phase I/II clinical trial of 24 patients in Taiwan. Oraxol, an innovative development in the treatment of cancer, is a... 
Printer Friendly Version 
January 22, 2018
Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA® (Ramucirumab) Combination Treatment in Gastric Cancer
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the completion of the first cohort of patients in its Phase 1b clinical trial of Oraxol (oral paclitaxel) plus CYRAMZA® (ramucirumab) in gastric cancer patients that failed previous chemotherapies. Oraxol, an innovative development in t... 
Printer Friendly Version 
January 16, 2018
Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol
BUFFALO, N.Y., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the United States Food and Drug Administration (“FDA”) has provided positive feedback on the design of the currently ongoing Phase III Clinical Trial for Oraxol, an innovative oral formulation of paclitaxel combined with HM30181A (... 
Printer Friendly Version 
January 08, 2018
Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
BUFFALO, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Chinese FDA has allowed the Investigational New Drug (IND) application for Oraxol, an oral formulation of paclitaxel. As previously announced, the IND application was submitted to the Chinese FDA in June 2017. In May 2017, Athe... 
Printer Friendly Version